HealthLinx Limited ABN 88 098 640 352 576 Swan Street Richmond VIC 3121 Telephone: +61 3 9208 4200 I Facsimile: +61 3 9208 4201 www.healthlinx.com.au OvPlex™ patent granted in Singapore 6 July 2012: HealthLinx Limited (ASX:HTX) has secured the grant of the patent application protecting its OvPlex™ ovarian cancer diagnostic product in Singapore, the fourth jurisdiction to secure patent coverage. Previously, patents have been granted in Australia, the United Kingdom and Hong Kong. The granting of this patent in Singapore is a significant milestone for the company; with Singapore one of the first international territories to market OvPlex™. OvPlex™ was launched in Singapore by HeatlhLinx’s distributor, INEX Innovations Exchange in October 2010 and has been well received in the market with expected sales targets exceeded by approximately 30%. HealthLinx’s incoming General Manager, Ms Vanessa Waddell stated that “the granting of the patent in Singapore provides INEX with the mechanism to protect market exclusivity for OvPlex™, an important outcome for the ongoing growth in OvPlex™ sales in this territory. Furthermore, this achievement strengthens our relationship with INEX as they lead the expansion of OvPlex™ sales across other Asian territories, including Malaysia and India.” “This patent is also a significant addition to HealthLinx’s growing patent portfolio,” Waddell concluded. Singapore Patent Number 165517 titled “An Assay to detect a Gynecological condition” draws priority from the Australian Patent Applications filed on 23rd April 2008 and 1st October 2008. The patent was granted to HealthLinx with the inventors, Dominic Autelitano, Tracey Edgell, Nick Gatsios and Leodevico Ilag named on the Patent. Enquiries Nick Gatsios (HealthLinx Limited) +61 3 9208 4200 Rudi Michelson (Monsoon Communications) +61 3 9620 3333
HTX Price at posting:
0.3¢ Sentiment: Buy Disclosure: Held
